JOHNSON & JOHNSON IS to “proactively delay” the rollout of its Covid-19 vaccine to Europe as US health agencies recommended a precautionary pause in the use of the jab.
The Food and Drugs Administration (FDA) and the Centres for Disease Control and Prevention (CDC) earlier issued a joint statement to recommend the vaccine be paused “out of an abundance of caution” after six cases of a rare type of blood clot were reported.
The agencies said that six people who experienced the clots were between the ages of 18 and 48, were women, and that symptoms occurred 6 to 13 days after vaccination.
The company itself has said that it will be working with authorities in both the US and Europe in regard to the reported blood clots.
It says that it is aware of “an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals” who have received its Covid-19 vaccine.
Ireland is scheduled to receive 40,800 doses of the single-shot J&J Covid-19 vaccine this month, and over 600,000 in total up to the end of June. The first scheduled delivery of 14,000 doses was expected in Ireland tomorrow.
“Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine,” Johnson & Johnson said in a statement.